Legend Biotech (LEGN) EPS (Weighted Average and Diluted) (2019 - 2025)
Legend Biotech (LEGN) reported EPS (Weighted Average and Diluted) of $3086.4 for Q4 2025, up 102.51% on a YoY basis from $1524.1 in Q4 2024, and up 105.78% quarter-over-quarter from -$53412.5 in Q3 2025.
Legend Biotech (LEGN) EPS (Weighted Average and Diluted) (2019 - 2025) Analysis & Trends
Legend Biotech has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at $3086.4 in Q4 2025.
- For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 102.51% year-over-year to $3086.4; the trailing twelve-month figure through Dec 2025 stood at $3086.4 (up 102.51% YoY), and the FY2025 full-year result was $40864.2, up 8513474.49% from the prior year.
- EPS (Weighted Average and Diluted) for Q4 2025 stood at $3086.4, up from -$53412.5 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $3086.4 in Q4 2025, with the low at -$948228.6 in Q2 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$77280.6 across 5 years, with a median of -$0.34 in 2021.
- Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) slumped 166912961.43% — and 2025, when it surged 102.51%.
- Legend Biotech's EPS (Weighted Average and Diluted) stood at -$0.3 in 2021, then sank by 36.7% to -$0.41 in 2022, then jumped by 40.88% to -$0.24 in 2023, then slumped by 50481343.97% to -$122916.7 in 2024, then soared by 102.51% to $3086.4 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at $3086.4 (Q4 2025), -$53412.5 (Q3 2025), and -$200348.4 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 6.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,086.42 |
| Sep 30, 2025 | -53,412.50 |
| Jun 30, 2025 | -200,348.39 |
| Mar 31, 2025 | -0.27 |
| Dec 31, 2024 | -122,916.67 |
| Sep 30, 2024 | -223,787.50 |
| Jun 30, 2024 | -948,228.57 |
| Mar 31, 2024 | -0.16 |
| Dec 31, 2023 | -0.24 |
| Sep 30, 2023 | -0.17 |
| Jun 30, 2023 | -0.57 |
| Mar 31, 2023 | -0.34 |
| Dec 31, 2022 | -0.41 |
| Sep 30, 2022 | -0.26 |
| Jun 30, 2022 | -0.62 |
| Mar 31, 2022 | -0.10 |
| Dec 31, 2021 | -0.30 |
| Sep 30, 2021 | -0.43 |
| Jun 30, 2021 | -0.33 |
| Mar 31, 2021 | -0.34 |